title: B-type natriuretic peptide as a marker of subclinical heart injury during mitoxantrone therapy in MS patients--preliminary study.
abstract: The aim of this study was to evaluate the plasma level changes of B-type natriuretic peptide (BNP), biochemical marker of heart failure, and echocardiographic parameters during mitoxantrone treatment in 22 multiple sclerosis (MS) patients (8 males, 14 females, mean age 37.1+/-6.6). Mitoxantrone (after mean cumulative dose of 58.0+/-7.0 mg/m(2)) did not alter left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), posterior wall thickness (PWT) and left ventricular end-diastolic volume (LVEDV). However, mean plasma level of BNP raised from 14.53+/-3.29 pg/ml at the baseline to 16.79+/-3.05 pg/ml and 18.83+/-4.90 pg/ml (P<0.01) after mean mitoxantrone dose of 30.7+/-5.9 mg/m(2) and 58.0+/-7.0 mg/m(2), respectively. These results strongly suggest subclinical myocardial dysfunction in mitoxantrone-treated group. We assume, that low-cost, repeated BNP measurements may be a good alternative for detection of early subtle myocardial injury in MS patients during routine mitoxantrone therapy.
authors.affiliation: Department of Neurology, Medical University, Jaczewskiego 8, 20-950 Lublin, Poland. pluchowski@wp.pl
authors.forename: Piotr
authors.initials: P
authors.lastname: Luchowski
authors.forename: Krystyna
authors.initials: K
authors.lastname: Mitosek-Szewczyk
authors.forename: Halina
authors.initials: H
authors.lastname: Bartosik-Psujek
authors.forename: Andrzej
authors.initials: A
authors.lastname: Rubaj
authors.forename: Marek
authors.initials: M
authors.lastname: Jankiewicz
authors.forename: Joanna
authors.initials: J
authors.lastname: Wojczal
authors.forename: Anna
authors.initials: A
authors.lastname: Szczepańska-Szerej
authors.forename: Zbigniew
authors.initials: Z
authors.lastname: Stelmasiak
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D004452:Echocardiography; D005260:Female; D006335:Heart Injuries / Q000097:blood / Q000139:chemically induced* / Q000150:complications / Q000175:diagnosis; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008942:Mitoxantrone / Q000009:adverse effects* / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D020097:Natriuretic Peptide, Brain / Q000097:blood*; D010865:Pilot Projects; D018709:Statistics, Nonparametric
chemical_list: D000970:Antineoplastic Agents; D015415:Biomarkers; D020097:Natriuretic Peptide, Brain; D008942:Mitoxantrone